	US 11,718,592 B2
	Oxadiazole derivative
Yoshiaki Isobe, Osaka (JP); Tomoyuki Tanaka, Osaka (JP); and Hirotaka Miyachi, Osaka (JP)
Assigned to Sumitomo Pharma Co., Ltd., Osaka (JP)
Filed by Sumitomo Pharma Co., Ltd., Osaka (JP)
Filed on Sep. 16, 2022, as Appl. No. 17/932,871.
Application 17/932,871 is a continuation of application No. 17/905,847, previously published as PCT/JP2021/010628, filed on Mar. 16, 2021.
Claims priority of application No. 2020-046138 (JP), filed on Mar. 17, 2020.
Prior Publication US 2023/0092498 A1, Mar. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 271/06 (2006.01); C07D 271/10 (2006.01); C07D 413/04 (2006.01); A61P 25/12 (2006.01); A61P 25/24 (2006.01); A61P 25/10 (2006.01); A61P 25/08 (2006.01)

CPC C07D 271/06 (2013.01) [A61P 25/08 (2018.01); A61P 25/10 (2018.01); A61P 25/12 (2018.01); A61P 25/24 (2018.01); C07D 271/10 (2013.01); C07D 413/04 (2013.01)]

30 Claims

1. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

a) 2-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]-2-methylpropanamide,

b) 2-[5-(4-chlorophenyl)-1,2,4-oxadiazol-3-yl]-2-methylpropanamide,

c) 5-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-1-methylpyrrolidin-2-one,

d) 5-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]-1-methylpyrrolidin-2-one,

e) (S)-5-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-1-methylpyrrolidin-2-one, and

f) (R)-5-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-1-methylpyrrolidin-2-one.